Radium223—Where Does It Fit in the Metastatic Castration-resistant Prostate Cancer Treatment Landscape?

2015 ◽  
Vol 11 (02) ◽  
pp. 135
Author(s):  
Tanya B Dorff ◽  
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Castration Resistant Prostate Cancer ◽  
Prostate Cancer Treatment ◽  
Castration Resistant ◽  
Significant Interest ◽  
Osseous Involvement ◽  
Defining Sequence

Radium223 is approved for symptomatic castration-resistant prostate cancer patients with osseous involvement. Selecting patients and defining sequence strategies are challenging, with the limited available data, but there is a trend toward greater impact in higher volume disease. Combination and/or consolidation strategies for Radium223 will be of significant interest as data emerge from ongoing trials.

scholarly journals Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment

2020 ◽  
Vol 9 (18) ◽  
pp. 6586-6596 ◽  
Author(s):  
Sandy Srinivas ◽  
Ateesha F. Mohamed ◽  
Sreevalsa Appukkuttan ◽  
Marc Botteman ◽  
Xinyi Ng ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Risk Preferences ◽  
Castration Resistant Prostate Cancer ◽  
Prostate Cancer Treatment ◽  
Castration Resistant

scholarly journals Physician preferences for non-metastatic castration-resistant prostate cancer treatment

BMC Urology ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Sandy Srinivas ◽  
Ateesha F. Mohamed ◽  
Sreevalsa Appukkuttan ◽  
Marc Botteman ◽  
Xinyi Ng ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Castration Resistant Prostate Cancer ◽  
Prostate Cancer Treatment ◽  
Castration Resistant
Sign in / Sign up

Export Citation Format

Share Document